Isotechnika Reports Development, Distribution and Licencing Agreement and Private Placement Financing With ILJIN Life Science co., Ltd., Amendment of Arrangements With Paladin Labs Inc., and Related Matters

EDMONTON, Canada, November 16, 2010 - Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Corporation")
today announced that it has entered into a Development, Distribution and
License Agreement (the "DDL") with ILJIN Life Science Co., Ltd ("ILJIN") for
the further clinical and commercial development of voclosporin for use in
transplant indications applicable to voclosporin. Under the DDL in exchange
for ILJIN funding the Corporation to perform a single Phase 3 clinical trial
in kidney transplantation through a combination of a license fee of $5
million USD and the purchase, in three tranches, of Common Shares from
treasury (the "Private Placement"), the Corporation has granted to ILJIN an
exclusive license to voclosporin for transplant and autoimmune indications
for the US and other regions outside of Canada, Israel, South Africa, Europe,
China, Taiwan and Hong Kong. The Corporation retains the rights over
voclosporin in Europe for future development and commercialization. The
Corporation will also use reasonable commercial efforts to facilitate the
appointment to the board of directors of the Corporation (the "Board") of two
(2) nominees of ILJIN. The DDL becomes effective on the date on which all
conditions and approvals required under the DDL (including shareholder and
regulatory approval, including the approval of the Toronto Stock Exchange
(the "TSX"), of the Private Placement) have been satisfied (the "Effective
Date").

Pursuant to various agreements between the Corporation and Paladin Labs
Inc. ("Paladin"), Paladin holds the patents and patent applications relating
to voclosporin, third party manufacturing and supply contracts, the right to
develop voclosporin in certain countries and the right to supply the
Corporation with its required bulk voclosporin. In order to support the
proposed transaction with ILJIN, Paladin has agreed to amend those agreements
(the "Paladin Amendments") in order to transfer to the Corporation certain
ownership and rights in and to all voclosporin patents and patent
applications and Paladin held voclosporin know-how and improvements to
voclosporin as of the Effective Date. Paladin has also entered into an
agreement with ILJIN to sell 12,500,000 Common Shares of Isotechnika to ILJIN
at closing.

ILJIN will purchase 90,700,000 Common Shares of the Corporation in three
tranches as per the table below.

      Private    Closing Date            Number of   Subscription  Price per
    Placement                               Shares         Amount      Share
      Tranche

        First    30 business days
                  after the Effective
                  Date                  11,500,000     $2,375,000     $0.207
                                                              USD        USD
       Second     On or before the
                   first anniversary
                   of the Effective
                   Date                 39,600,000     $8,500,000     $0.215
                                                              USD        USD
        Third     On or before the
                   second anniversary
                   of the Effective
                   Date                 39,600,000     $9,000,000     $0.227
                                                              USD        USD

Because greater than 25% of the current outstanding Common Shares will be
issued pursuant to the Private Placement, the rules of the TSX require that
the Corporation obtain Shareholder approval of the Private Placement and the
Corporation is calling and plans to hold a special meeting (the "Meeting") of
shareholders as soon as practically possible, which meeting is expected to be
held on, or about, December 15, 2010.

"The additional funding by ILJIN for the voclosporin program in
transplantation and in particular the initiation of a global Phase 3 clinical
trial in transplant is a significant milestone in the future
commercialization of voclosporin," stated Dr. Robert Foster, President and
CEO. "We are very excited to have ILJIN Life Science Co., Ltd. as a partner.
ILJIN Life Science Co., Ltd. is a member company of the ILJIN Group, a global
conglomerate based in Seoul, South Korea, which last year had approximately
US$2 billion of revenue."

The Board reviewed the DDL and Private Placement transactions and
concluded that the proposed transaction with ILJIN provides:

1. the means to advance the development of voclosporin through a Phase 3
trial in transplantation;

2. a unique opportunity for the Corporation to actively obtain 50% of net
profit for the sale of voclosporin in the US, and 50% of net profit for the
sale of voclosporin in other countries in which ILJIN directly commercializes
voclosporin, which is significantly greater than standard royalty rates of
10-15% of net profit; and

3. a viable opportunity for the stakeholders in the Corporation to better
realize the full value of the Corporation's voclosporin asset.

The Board has approved the DDL, the Private Placement and the Paladin
Amendments and will be recommending that shareholders approve the
transactions with ILJIN and vote in favour of the Private Placement.

"We are very pleased to announce our investment in Isotechnika and the
transplant field," said Daniel S. Park, Executive Vice President of ILJIN
Life Science Co., Ltd. and ILJIN Group. "We believe this is a significant
opportunity for ILJIN to expand its business in the life sciences field."

Board Composition

In addition the Board has resolved to amend the by-laws of the
Corporation to lower the minimum ratio of directors of the Corporation that
have to be resident Canadians to both assist in accommodating its commitment
to ILJIN to appoint two nominees to the Board and to match the existing
residency requirements set forth in the Business Corporations Act (Alberta)
(the "ABCA").

At the Meeting, shareholders will be asked to confirm the amendment to
the by-laws made by the directors to require that only one quarter (1/4) of
the directors be resident Canadians as is the minimum requirement in the ABCA
and that the by-laws of the Corporation be amended to remove the requirement
that the Board shall not transact business at a meeting, other than filling a
vacancy in the Board, unless at least half of the directors present are
resident Canadians.

As well shareholders will be asked to vote in favour of the election of
ILJIN nominees at the Meeting and such other nominees as may be required in
order for the Board to comply with the residency requirements of the ABCA,
all of which will be set forth in the Information Circular that will be sent
to shareholders for purposes of the Meeting.

The Corporation is pleased to announce that Dr. Jing Lou, Co-founder,
Chief Executive Officer and a director of Isotechnika's partner, 3SBio, Inc.,
has joined the Board effective November 9, 2010 filling the vacancy created
by the earlier resignation of David MacNaughtan. The Corporation also
announces that Nancy Harrison has resigned from the Board effective November
9, 2010. The Corporation and the Board thank her for her service as a
director.

About ILJIN Group

Information on ILJIN Group can be found at www.iljin.co.kr.

About Isotechnika Pharma Inc.

Isotechnika Pharma Inc. is a biopharmaceutical company focused on the
discovery and development of immunomodulating therapeutics that are designed
to offer advantages over other currently available treatments. There is a
significant unmet medical need in the treatment of both solid organ
transplantation and autoimmune disease. It is estimated that the market
potential will be $3 billion annually in sales for calcineurin inhibitors
such as voclosporin in 2010.

Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika Pharma can
be found at www.isotechnika.com or www.SEDAR.com.

We seek Safe Harbor.

    For further information:

    Dr. Robert Foster
    President & CEO
    rfoster@isotechnika.com
    +1-780-487-1600 (Ext 247)

    Dennis Bourgeault
    CFO
    dbourgeault@isotechnika.com
    +1-780-487-1600 (Ext 226)

For further information: Dr. Robert Foster, President & CEO, rfoster at isotechnika.com, +1-780-487-1600 (Ext 247); Dennis Bourgeault, CFO, dbourgeault at isotechnika.com, +1-780-487-1600 (Ext 226)